Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 3, 2005, Pages 487-503

  Warrington, Jill S ^a   Shaw, Leslie M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CYP3A; glucuronidation; immunosuppressant; MRP2; P glycoprotein; pharmacogenetics; transporters

Indexed keywords

CARRIER PROTEIN; DRUG; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; DRUG INTERACTION; HUMAN; METABOLISM; PHARMACOGENETICS; RACE; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; CARRIER PROTEINS; CONTINENTAL POPULATION GROUPS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; TISSUE DISTRIBUTION;

EID: 33747827892     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.3.487     Document Type: Review

References (171)

1. BARONE CP, MARTIN-WATSON AL, BARONE GW: The postoperative care of the adult renal transplant recipient. Medsurg. Nurs. (2004) 13(5):296-302; quiz 303.
2. HABERAL M, DALGIC A: New concepts in organ transplantation. Transplant. Proc. (2004) 36(5):1219-1224. (Pubitemid 38902942)
3. SMITH JM, MCDONALD RA: Renal transplantation in adolescents. Adolesc Med. Clin. (2005) 16(1):201-214. (Pubitemid 40018572)
4. MACDONALD A, SCAROLA J, BURKE JT, ZIMMERMAN JJ: Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin. Ther. (2000) 22(Suppl. B):B101-B121. (Pubitemid 30306050)
5. SHAW LM, KORECKA M, DENOFRIO D, BRAYMAN KL: Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin. Biochem. (2001) 34(1):17-22. (Pubitemid 32178501)
6. ANGLICHEAU D, LEGENDRE C, THERVET E: Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation (2004) 78(3):311-315. (Pubitemid 39095394)
7. CATTANEO D, PERICO N, REMUZZI G: From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am. J. Transplant. (2004) 4(3):299-310. (Pubitemid 38282284)
8. DEIERHOI MH, HAUG M 3rd: Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy. Clin. Transplant. (2000) 14(5):439-448.
9. ROSENBAUM SE, BAHETI G, TRULL AK, AKHLAGHI F: Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther. Drug Monit. (2005) 27(2):116-122. (Pubitemid 40463636)
10. AW MM, BROWN NW, ITSUKA T, et al.: Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl. (2003) 9(4):383-388. (Pubitemid 36443052)
11. DIPCHAND AI, PIETRA B, MCCRINDLE BW, ROSEBROOK-BICKNELL HL, BOUCEK MM: Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J. Heart Lung Transplant. (2001) 20(10):1035-1043. (Pubitemid 32930108)
12. FILLER G, FOSTER J, BERARD R, MAI I, LEPAGE N: Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant. Proc. (2004) 36(5):1327-1331. (Pubitemid 38902969)
13. KIM JS, AVILES DH, SILVERSTEIN DM, LEBLANC PL, MATTI VEHASKARI V: Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr. Transplant. (2005) 9(2):162-169. (Pubitemid 40476842)
14. DEL MAR FERNANDEZ DE GATTA M, SANTOS-BUELGA D, DOMINGUEZ-GIL A, GARCIA MJ: Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. (2002) 41(2):115-135. (Pubitemid 34264038)
15. ETTENGER RB, GRIMM EM: Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am. J. Kidney Dis. (2001) 38(4 Suppl. 2):S22-S28. (Pubitemid 32916886)
16. OELLERICH M, ARMSTRONG VW, STREIT F, WEBER L, TONSHOFF B: Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin. Biochem. (2004) 37(6):424-428. (Pubitemid 38746635)
17. SINDHI R, WEBBER S, VENKATARAMANAN R, et al.: Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation (2001) 72(5):851-855. (Pubitemid 32879857)
18. HOYER PF, ETTENGER R, KOVARIK JM, et al.: Everolimus in pediatric de nova renal transplant patients. Transplantation (2003) 75(12):2082-2085. (Pubitemid 36793297)
19. RUMBO C, SHNEIDER BL, EMRE SH: Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. Pediatr Transplant. (2004) 8(6):571-575. (Pubitemid 40052355)
20. CHAPMAN JR, O'CONNELL PJ, BOVINGTON KJ, ALLEN RD: Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. Transplantation. (1996) 61(12):1699-1704. (Pubitemid 26242007)
21. MUNDA R, SCHROEDER TJ, PEDERSEN SA, et al.: Cyclosporine pharmacokinetics in pancreas transplant recipients. Transplant. Proc. (1988) 20(2 Suppl. 2):487-490.
22. JOHNSON HJ, SWAN SK, HEIM-DUTHOY KL, NICHOLLS AJ, TSINA I, TARNOWSKI T: The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin. Pharmacol. Ther. (1998) 63(5):512-518. (Pubitemid 28277272)
23. KAPLAN B, MEIER-KRIESCHE HU, FRIEDMAN G, et al.: The effect of renal insufficiency on mycophenolic acid protein binding. J. Clin. Pharmacol. (1999) 39(7):715-720.
24. MEIER-KRIESCHE HU, SHAW LM, KORECKA M, KAPLAN B: Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther. Drug Monit. (2000) 22(1):27-30. (Pubitemid 30083091)
25. SHAW LM, MICK R, NOWAK I, KORECKA M, BRAYMAN KL: Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J. Clin. Pharmacol. (1998) 38(3):268-275. (Pubitemid 28144932)
26. WALKER S, HABIB S, ROSE M, YACOUB M, BANNER N: Clinical use and bioavailability of tacrolimus in heartlung and double lung transplant recipients with cystic fibrosis. Transplant. Proc. (1998) 30(4):1519-1520. (Pubitemid 28309670)
27. STAATZ CE, WILLIS C, TAYLOR PJ, TETT SE: Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin. Pharmacol. Ther. (2002) 72(6):660-669. (Pubitemid 36021005)
28. SIROLIMUS Rapamune oral solution (sirolimus). Wyeth-Ayerst Laboratories, Package insert, Princeton NJ, USA (1999).
29. KOVARIK JM, SABIA HD, FIGUEIREDO J, et al.: Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin. Pharmacol. Ther. (2001) 70(5):425-430. (Pubitemid 33135321)
30. SCHUSZIARRA V, ZIEKURSCH V, SCHLAMP R, SIEMENSEN HC: Pharmacokinetics of azathioprine under haemodialysis. Int. J. Clin. Pharmacol. Biopharm. (1976) 14(4):298-302.
31. BISTRUP C, NIELSEN FT, JEPPESEN UE, DIEPERINK H: Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol. Dial. Transplant. (2001) 16(2):373-377. (Pubitemid 32123929)
32. DAHAN A, ALTMAN H: Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur. J. Clin. Nutr. (2004) 58(1):1-9. (Pubitemid 38159306)
33. DRESSER GK, SCHWARZ UI, WILKINSON GR, KIM RB: Coordinate induction of both cytochrome P4503A and MDR1 by St John?s wort in healthy subjects. Clin. Pharmacol. Ther. (2003) 73(1):41-50. (Pubitemid 36158485)
34. TAN KK, TRULL AK, UTTRIDGE JA et al.: Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther. (1995) 57(4):425-433.
35. MAI I, STORMER E, BAUER S, KRUGER H, BUDDE K, ROOTS I: Impact of St John?s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol. Dial. Transplant. (2003) 18(4):819-822. (Pubitemid 36432268)
36. BEKERSKY I, DRESSLER D, MEKKI QA: Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J. Clin. Pharmacol. (2001) 41(2):176-182. (Pubitemid 32106056)
37. EGASHIRA K, FUKUDA E, ONGA T et al.: Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation (2003) 75(7):1057. (Pubitemid 36438541)
38. EGASHIRA K, OHTANI H, ITOH S et al.: Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab. Dispos. (2004) 32(8):828-833. (Pubitemid 38955612)
39. ZIMMERMAN JJ: Exposure-response relationships and drug interactions of sirolimus. AAPS J. (2004) 6(4):e28.
40. ZIMMERMAN JJ, FERRON GM, LIM HK, PARKER V: The effect of a highfat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J. Clin. Pharmacol. (1999) 39(11):1155-1161. (Pubitemid 30644018)
41. KOVARIK JM, HARTMANN S, FIGUEIREDO J, et al.: Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. (2002) 22(2):154-159. (Pubitemid 34112877)
42. KOVARIK JM, NOE A, BERTHIER S et al.: Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. J. Clin. Pharmacol. (2003) 43(2):141-147. (Pubitemid 36125940)
43. MORISSETTE P, ALBERT C, BUSQUE S, ST-LOUIS G, VINET B: In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther. Drug Monit. (2001) 23(5):520-525. (Pubitemid 32912273)
44. PESCOVITZ MD, GUASCH A, GASTON R, et al.: Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am. J. Transplant. (2003) 3(12):1581-1586. (Pubitemid 37541517)
45. FITZSIMMONS WE, BEKERSKY I, DRESSLER D, RAYE K, HODOSH E, MEKKI Q: Demographic considerations in tacrolimus pharmacokinetics. Transplant. Proc. (1998) 30(4):1359-1364. (Pubitemid 28309604)
46. KOVARIK JM, HSU CH, MCMAHON L, BERTHIER S, RORDORF C: Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin. Pharmacol. Ther. (2001) 70(3):247-254. (Pubitemid 32868488)
47. CHOCAIR PR, DULEY JA, SABBAGA E, ARAP S, SIMMONDS HA, CAMERON JS: Fast and slow methylators: do racial differences influence risk of allograft rejection? J. Med. (1993) 86(6):359-363. (Pubitemid 23197325)
48. WUSK B, KULLAK-UBLICK GA, RAMMERT C, VON ECKARDSTEIN A, FRIED M, RENTSCH KM: Thiopurine Smethyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. Eur. J. Clin. Pharmacol. (2004) 60(1):5-10. (Pubitemid 38476965)
49. LINDHOLM A, WELSH M, ALTON C, KAHAN BD: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin. Pharmacol. Ther. (1992) 52(4):359-371.
50. MIN DI, LEE M KU, YM, FLANIGAN M: Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin. Pharmacol. Ther. (2000) 68(5):478-486.
51. STEIN CM, SADEQUE AJ, MURRAY JJ, WANDEL C, KIM RB, WOOD AJ: Cyclosporine pharmacokinetics and pharmacodynamics in African-American and white subjects. Clin. Pharmacol. Ther. (2001) 69(5):317-323. (Pubitemid 32477072)
52. SHAW LM, KORECKA M, ARADHYE S et al.: Mycophenolic acid area under the curve values in African-American and Caucasian renal transplant patients are comparable. J. Clin. Pharmacol. (2000) 40(6):624-633.
53. NEYLAN JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation (1998) 65(4):515-523. (Pubitemid 28136494)
54. ZHENG H, ZEEVI A, SCHUETZ E, et al.: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. (2004) 44(2):135-140. (Pubitemid 38114311)
55. DIRKS NL, HUTH B, YATES CR, MEIBOHM B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther. (2004) 42(12):701-718. (Pubitemid 39625130)
56. SALMELA KT, KYLLONEN LE: Two decades of experience with cyclosporine in renal transplantation in Helsinki. Transplant. Proc. (2004) 36(2 Suppl.):94S-98S. (Pubitemid 38373839)
57. PERRY I, NEUBERGER J: Immunosuppression: towards a logical approach in liver transplantation. Clin. Exp. Immunol. (2005) 139(1):2-10. (Pubitemid 40066121)
58. POLLARD SG: Pharmacologic monitoring and outcomes of cyclosporine. Transplant. Proc. (2004) 36(2 Suppl.):404S-407S. (Pubitemid 38373899)
59. BOOTS JM, CHRISTIAANS MH, VAN HOOFF JP: Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs (2004) 64(18):2047-2073. (Pubitemid 39280373)
60. THERVET E, LEGENDRE C, BEAUNE P, ANGLICHEAU D: Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics (2005) 6(1):37-47. (Pubitemid 40220669)
61. KOBAYASHI M, SAITOH H, KOBAYASHI M, TADANO K, TAKAHASHI Y, HIRANO T: Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats. J. Pharmacol. Exp. Ther. (2004) 309(3):1029-1035. (Pubitemid 38669688)
62. MACKENZIE PI: Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther. Drug Monit. (2000) 22(1):10-13.
63. PICARD N, RATANASAVANH D, PREMAUD A, LE MEUR Y, MARQUET P: Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos. (2005) 33(1):139-146. (Pubitemid 40023525)
64. CUMMINS CL, JACOBSEN W, CHRISTIANS U, BENET LZ: CYP3A4- transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther. (2004) 308(1):143-155. (Pubitemid 38090712)
65. KIRCHNER GI, MEIER-WIEDENBACH I, MANNS MP: Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. (2004) 43(2):83-95. (Pubitemid 38283132)
66. EL-AZHARY RA: Azathioprine: current status and future considerations. Int. J. Dermatol. (2003) 42(5):335-341. (Pubitemid 36681712)
67. FIREMAN M, DIMARTINI AF, ARMSTRONG SC, COZZA KL: Immunosuppressants. Psychosomatics (2004) 45(4):354-360. (Pubitemid 38823612)
68. TONSHOFF B, HOCKER B, WEBER LT: Steroid withdrawal in pediatric and adult renal transplant recipients. Pediatr. Nephrol. (2005) 20(3):409-417. (Pubitemid 40309953)
69. CANTAROVICH M, BESNER JG, BARKUN JS, ELSTEIN E, LOERTSCHER R: Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin. Transplant. (1998) 12(3):243-249. (Pubitemid 28269248)
70. CANTAROVICH M, BARKUN JS, TCHERVENKOV JI, BESNER JG, ASPESLET L, METRAKOS P: Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation (1998) 66(12):1621-1627. (Pubitemid 29034981)
71. CANTAROVICH M, ELSTEIN E, DE VARENNES B, BARKUN JS: Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation (1999) 68(12):1839-1842. (Pubitemid 30027333)
72. EINECKE G, MAI I, FRITSCHE L, et al.: The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol. Dial. Transplant. (2004) 19(1):215-222. (Pubitemid 38072636)
73. MUELLER EA, KOVARIK JM, VAN BREE JB, LISON AE, KUTZ K: Safety and steady-state pharmacokinetics of a new oral formulation of cyclosporin A in renal transplant patients. Transpl. Int. (1994) 7(Suppl. 1):S267-S269.
74. ARMSTRONG VW, OELLERICH M: New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin. Biochem. (2001) 34(1):9-16. (Pubitemid 32178500)
75. KAHAN BD, DUNN J, FITTS C, et al.: Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation (1995) 59(4):505-511.
76. KAHAN BD, WELSH M, SCHOENBERG L, et al.: Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation (1996) 62(5):599-606. (Pubitemid 26313901)
77. CHOCAIR PR, DULEY JA, SIMMONDS HA, CAMERON JS: The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. (1992) 53(5):1051-1056.
78. WEINSHILBOUM RM, SLADEK SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. (1980) 32(5):651-662. (Pubitemid 10061685)
79. KRYNETSKI EY, SCHUETZ JD, GALPIN AJ, PUI CH, RELLING MV, EVANS WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. USA (1995) 92(4):949-953.
80. OTTERNESS D, SZUMLANSKI C, LENNARD L, et al.: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. (1997) 62(1):60-73. (Pubitemid 27327100)
81. SZUMLANSKI C, OTTERNESS D, HER C, et al.: Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. (1996) 15(1):17-30. (Pubitemid 26029354)
82. TAI HL, KRYNETSKI EY, YATES CR et al.: Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. (1996) 58(4):694-702. (Pubitemid 26086658)
83. YATES CR, KRYNETSKI EY, LOENNECHEN T, et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. (1997) 126(8):608-614. (Pubitemid 27172187)
84. SORIA-ROYER C, LEGENDRE C, MIRCHEVA J, PREMEL S, BEAUNE P, KREIS H: Thiopurine-methyl-transferase activity to assess azathioprine myelotoxicity in renal transplant recipients. Lancet (1993) 341(8860):1593-1594. (Pubitemid 23170482)
85. GANIERE-MONTEIL C, PINEAU A, KERGUERIS MF, AZOULAY C, BOURIN M: Thiopurine methyl transferase activity: new extraction conditions for high-performance liquid chromatographic assay. J. Chromatogr. B Biomed. Sci. Appl. (1999) 727(1- 2):235-239. (Pubitemid 29189296)
86. SPIRE-VAYRON DE LA MOUREYRE C, DEBUYSERE H, SABBAGH N, et al.: Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum. Mutat. (1998) 12(3):177-185. (Pubitemid 28384589)
87. KUEHL P, ZHANG J, LIN Y, et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27(4):383-391. (Pubitemid 32268418)
88. MIN DI, ELLINGROD VL, MARSH S, MCLEOD H: CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. (2004) 26(5):524-528. (Pubitemid 39314320)
89. YATES CR, ZHANG W, SONG P, et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. (2003) 43(6):555-564. (Pubitemid 36613114)
90. GUENGERICH FP: Cytochromes P450, drugs, and diseases. Mol. Interv. (2003) 3(4):194-204.
91. LOWN KS, KOLARS JC, THUMMEL KE, et al.: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. (1994) 22(6):947-955. (Pubitemid 24377372)
92. ANGLICHEAU D, LE CORRE D, LECHATON S, et al.: Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. (2005) 5(3):595-603. (Pubitemid 40313352)
93. AMIRIMANI B, NING B, DEITZ AC, WEBER BL, KADLUBAR FF, REBBECK TR: Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. (2003) 42(4):299-305. (Pubitemid 38054375)
94. FLOYD MD, GERVASINI G, MASICA AL, et al.: Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics (2003) 13(10):595-606. (Pubitemid 37311146)
95. CHOU FC, TZENG SJ, HUANG JD: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos. (2001) 29(9):1205-1209.
96. TSUCHIYA N, SATOH S, TADA H, LI Z et al.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation (2004) 78(8):1182-1187. (Pubitemid 39426437)
97. HESSELINK DA, VAN GELDER T, VAN SCHAIK RH, et al.: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. (2004) 76(6):545-556. (Pubitemid 39601545)
98. HESSELINK DA, VAN SCHAIK RH, VAN DER HEIDEN IP, et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. (2003) 74(3):245-254. (Pubitemid 37083100)
99. VON AHSEN N, RICHTER M, GRUPP C, RINGE B, OELLERICH M, ARMSTRONG VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. (2001) 47(6):1048-1052. (Pubitemid 32493590)
100. MACPHEE IA, FREDERICKS S, MOHAMED M, et al.: Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation (2005) 79(4):499-502. (Pubitemid 40280186)
101. THERVET E, ANGLICHEAU D, KING B, et al.: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 76(8):1233-1235. (Pubitemid 37339651)
102. HAUFROID V, MOURAD M, VAN KERCKHOVE V, et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 14(3):147-154. (Pubitemid 38373108)
103. MACKENZIE PI, OWENS IS, BURCHELL B, et al.: The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics (1997) 7(4):255-269. (Pubitemid 27358064)
104. WELLS PG, MACKENZIE PI, CHOWDHURY JR, et al.: Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. (2004) 32(3):281-290. (Pubitemid 38263885)
105. BULLINGHAM RE, NICHOLLS AJ, KAMM BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. (1998) 34(6):429-455. (Pubitemid 28273453)
106. SHIPKOVA M, ARMSTRONG VW, WIELAND E, et al.: Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol. (1999) 126(5):1075-1082. (Pubitemid 29123740)
107. SHIPKOVA M, SCHUTZ E, ARMSTRONG VW, NIEDMANN PD, OELLERICH M, WIELAND E: Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin. Chem. (2000) 46(3):365-372. (Pubitemid 30152262)
108. WIELAND E, SHIPKOVA M, SCHELLHAAS U, et al.: Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin. Biochem. (2000) 33(2):107-113. (Pubitemid 30212818)
109. NAWROCKI A, SOLARI S, KANG J, SHAW LM: Mycophenolic Acid. Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2005).
110. VILLENEUVE L, GIRARD H, FORTIER LC, GAGNE JF, GUILLEMETTE C: Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7- ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. (2003) 307(1):117-128. (Pubitemid 37151897)
111. BERNARD O, GUILLEMETTE C: The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. (2004) 32(8):775-778. (Pubitemid 38955603)
112. BHASKER CR, MCKINNON W, STONE A, et al.: Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics. (2000) 10(8):679-685.
113. HOLTHE M, KLEPSTAD P, ZAHLSEN K, et al.: Morphine glucuronideto- morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. (2002) 58(5):353-356. (Pubitemid 34983926)
114. SHIPKOVA M, ARMSTRONG VW, WEBER L, et al.: Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther. Drug Monit. (2002) 24(3):390-399. (Pubitemid 34553205)
115. COURT MH, KRISHNASWAMY S, HAO Q, et al.: Evaluation of 3′-azido-3′- deoxythymidine, morphine, and codeine as probe substrates for UDPglucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos. (2003) 31(9):1125-1133. (Pubitemid 37048284)
116. HOFFMANN U, KROEMER HK: The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev. (2004) 36(3-4):669-701. (Pubitemid 39453069)
117. CHRISTIANS U: Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther. Drug Monit. (2004) 26(2):104-106. (Pubitemid 38501200)
118. CASCORBI I, GERLOFF T, JOHNE A et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 69(3):169-174. (Pubitemid 32225417)
119. ISHIKAWA T, HIRANO H, ONISHI Y, SAKURAI A, TARUI S: Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab. Pharmacokinet. (2004) 19(1):1-14.
120. JOHNE A, KOPKE K, GERLOFF T, et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. (2002) 72(5):584-594. (Pubitemid 36237730)
121. GOTO M, MASUDA S, SAITO H, et al.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than P-gp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 12(6):451-457. (Pubitemid 34913527)
122. TANABE M, IEIRI I, NAGATA N, et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297(3):1137-1143. (Pubitemid 32472514)
123. HOFFMEYER S, BURK O, VON RICHTER O, et al.: Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97(7):3473-3478. (Pubitemid 30183327)
124. ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P, et al.: Association of the multidrug resistance-1 gene singlenucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. (2003) 14(7):1889-1896. (Pubitemid 36750485)
125. BONHOMME-FAIVRE L, DEVOCELLE A, SALIBA F, et al.: MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in livertransplant recipients. Transplantation (2004) 78(1):21-25.
126. GERLOFF T, SCHAEFER M, JOHNE A et al.: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. (2002) 54(6):610-616. (Pubitemid 36002588)
127. SAKAEDA T, NAKAMURA T, HORINOUCHI M, et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. (2001) 18(10):1400-1404. (Pubitemid 32977244)
128. KIM RB, LEAKE BF, CHOO EF, et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 70(2):189-199. (Pubitemid 32777772)
129. SHAW LM, NOWAK I: Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther. Drug Monit. (1995) 17(6):685-689.
130. SUZUKI H, SUGIYAMA Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. (2002) 54(10):1311-1331. (Pubitemid 35284255)
131. ASANO T, NISHIMOTO K, HAYAKAWA M: Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant. Proc. (2004) 36(7):2096-2097. (Pubitemid 39424338)
132. KUSUHARA H, SUGIYAMA Y: Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control. Release. (2002) 78(1-3):43-54. (Pubitemid 34081852)
133. HIROUCHI M, SUZUKI H, ITODA M et al.: Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. (2004) 21(5):742-748. (Pubitemid 39011294)
134. MORIYA Y, NAKAMURA T, HORINOUCHI M, et al.: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. (2002) 25(10):1356-1359. (Pubitemid 39663201)
135. YAMAUCHI A, IEIRI I, KATAOKA Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation (2002) 74(4):571-572.
136. GAO Y, XIONG D, YANG M, et al.: Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia (2004) 18(3):513-520. (Pubitemid 38425866)
137. GOTZL M, WALLNER J, GSUR A, et al.: MDR1 gene expression in lymphocytes of patients with renal transplants. Nephron. (1995) 69(3):277-280.
138. BECQUEMONT L, CAMUS M, KRIAA F, BARBU V, CHARPENTIER B, JAILLON P: Low levels of lymphocyte MDR1 gene expression during early renal transplantation in patients treated with tacrolimus. Fundam. Clin. Pharmacol. (2000) 14(3):225-229. (Pubitemid 30413494)
139. PARASRAMPURIA DA, LANTZ MV, BIRNBAUM JL, VINCENTI FG, BENET LZ: Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J. Clin. Pharmacol. (2002) 42(3):304-311. (Pubitemid 34163477)
140. ZACHER T, THIELE B, WASSMUTH R, ALBERT FW: Cyclosporine A sensitivity in vitro and P-glycoprotein expression in patients on dialysis and after kidney transplantation. Transpl. Immunol. (2000) 8(2):147-150.
141. HYLE JW, SHAW RJ, REINES D: Functional distinctions between IMP dehydrogenase genes in providing mycophenolate resistance and guanine prototrophy to yeast. J. Biol. Chem. (2003) 278(31):28470-28478. (Pubitemid 36935749)
142. THERVET E, ANGLICHEAU D, LEGENDRE C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. (2001) 22(7):331-337. (Pubitemid 33043089)
143. GLANDER P, HAMBACH P, BRAUN KP et al.: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. (2004) 4(12):2045-2051. (Pubitemid 39611633)
144. BROGAN IJ, PRAVICA V, HUTCHINSON IV: Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2. Transpl. Immunol. (2000) 8(2):139-141.
145. GUERINI D: Calcineurin: not just a simple protein phosphatase. Biochem. Biophys. Res. Commun. (1997) 235(2):271-275. (Pubitemid 27313694)
146. LIN MJ, PARSIA SS, PAPOLOS DF, LACHMAN HM: Highly polymorphic sequence variation in calcineurin B coding region (PPP3R1). Hum. Mol. Genet. (1994) 3(3):520. (Pubitemid 24083922)
147. SCHULMAN SL, PALMER J, DUNN S, KAISER BA, POLINSKY MS, BALUARTE HJ: Effect of recipient?s race on pediatric renal allograft survival: a singlecenter study. Pediatrics (1992) 89(6 Pt 1):1055-1058.
148. EMOVON OE, KING JA, HOLT CO, SINGLETON B, HOWELL D, BROWNE BJ: Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. Clin. Transplant. (2003) 17(3):206-211. (Pubitemid 36748466)
149. MACPHEE IA, FREDERICKS S, TAI T et al.: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. (2004) 4(6):914-919. (Pubitemid 38745590)
150. JIRASIRITHAM S, SUMETHKUL V, MAVICHAK V, NA-BANGCHANG K: The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant. Proc. (2004) 36(7):2076-2078. (Pubitemid 39424331)
151. CHRISTIANS U, POKAIYAVANICHKUI T, CHAN L: Tacrolimus. Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2005).
152. JOHNSTON A, HOLT DW: Cyclosporine. Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2005).
153. PIEPER AK, BUHLE F, BAUER S, et al.: The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol. Dial. Transplant. (2004) 19(10):2630-2633. (Pubitemid 39360114)
154. MCLAUGHLIN GE, ROSSIQUE-GONZALEZ M, GELMAN B, KATO T: Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. Transplant. Proc. (2000) 32(3):665-668. (Pubitemid 30254446)
155. SCHONDER KS, SHULLO MA, OKUSANYA O: Tacrolimus and lopinavir/ ritonavir interaction in liver transplantation. Ann. Pharmacother. (2003) 37(12):1793-1796. (Pubitemid 37466573)
156. SHEIKH AM, WOLF DC, LEBOVICS E, GOLDBERG R, HOROWITZ HW: Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation (1999) 68(2):307-309. (Pubitemid 29360297)
157. CLAESSON K, BRATTSTROM C, BURKE JT: Sirolimus and erythromycin interaction: two cases. Transplant. Proc. (2001) 33(3):2136. (Pubitemid 33762659)
158. ARONSON J: Serious drug interactions. Practitioner (1993) 237(1531):789-791.
159. CATTANEO D, PERICO N, GASPARI F, GOTTI E, REMUZZI G: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. (2002) 62(3):1060-1067. (Pubitemid 35316738)
160. PODDER H, STEPKOWSKI SM, NAPOLI KL, et al.: Pharmacokinetic interactions augment toxicities of sirolimus/ cyclosporine combinations. J. Am. Soc. Nephrol. (2001) 12(5):1059-1071. (Pubitemid 32378348)
161. JUSKO WJ, FERRON GM, MIS SM, KAHAN BD, ZIMMERMAN JJ: Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J. Clin. Pharmacol. (1996) 36(12):1100-1106. (Pubitemid 27056936)
162. PAPE L, FROEDE K, STREHLAU J, EHRICH JH, OFFNER G: Alterations of cyclosporin A metabolism induced by mycophenolate mofetil. Pediatr. Transplant. (2003) 7(4):302-304. (Pubitemid 36988286)
163. ZUCKER K, ROSEN A, TSAROUCHA A et al.: Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl. Immunol. (1997) 5(3):225-232. (Pubitemid 27489255)
164. DEL TACCA M: Prospects for personalized immunosuppression: pharmacologic tools - a review. Transplant. Proc. (2004) 36(3):687-689. (Pubitemid 38534360)
165. BACKMAN L, KREIS H, MORALES JM, WILCZEK H, TAYLOR R, BURKE JT: Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br. J. Clin. Pharmacol. (2002) 54(1):65-68. (Pubitemid 36124756)
166. FLECHNER SM, GOLDFARB D, MODLIN C, et al.: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 74(8):1070-1076. (Pubitemid 35216097)
167. YOKOGAWA K, SHIMADA T, HIGASHI Y, et al.: Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem. Pharmacol. (2002) 63(4):777-783. (Pubitemid 34457711)
168. http://www.prometheuslabs.com/212a.asp?nav=products Vol. May (2005)
169. http://medicine.iupui.edu/flockhart/ table.htm. Vol. May (2005).
170. http://www.imm.ki.se/cypalleles/ cyp3a5.htm Vol. May (2005)
171. http://www.medscape.com/viewprogram/ 2913-pnt Vol. May (2005).